Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Alcohol. 2016 Nov 10;58:107–125. doi: 10.1016/j.alcohol.2016.07.011

Table 4.

Trait correlations between serum 3α,5α-THDOC levels and behavioral or neurochemical phenotypes across the BXD strains.

GN ID Phenotypes Spearman
17452 3α,5α-THDOC in CTL males and females Reference r p n
17453 3α,5α-THDOC in CTL males Present results 0.93 0.0000 18
12961 Ethanol response, ethanol intake using a 2-bottle choice test, 2h access after cycle 4 of air exposure only
(control for CIE) in vapor chambers (average of 5 days ethanol intake [g/kg/2h])		 Lopez M. F. et al.,
Unpublished		 0.75 0.0001 19
12963 Ethanol response, ethanol intake using a 2-bottle choice test, 2 h access after the second cycle of air exposure
(control for CIE) in vapor chamber (average of 5 days ethanol intake, young adult males or females [g/kg/2h]		 Jones S. R. et al.,
Unpublished		 0.56 0.0112 19
12810 Control for ethanol response, 3,4-dihydroxyphenylacetic acid levels (DOPAC) in hindbrain tissue 72 h after the
5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1)
[ng/mg]		 Jones S. R. et al.,
Unpublished		 0.60 0.0079 18
12811 Control for ethanol response, dopamine levels (DA) in hindbrain tissue 72 h after the 5th air control cycle of
vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg]		 Jones S. R. et al.,
Unpublished		 0.52 0.0265 18
12813 Control for ethanol response, homovanillic acid (HVA, a dopamine metabolite) level in hindbrain tissue 72 h after
the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1)
[ng/mg]		 Jones S. R. et al.,
Unpublished		 0.56 0.0137 18
12812 Control for ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in hindbrain
tissue 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or females (Dec
2009 Cohort 1) [ng/mg]		 Jones S. R. et al.,
Unpublished		 0.56 0.0137 18
13576 Ethanol (20% v/v) consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in control
females, within-group change (phase 2 minus phase 1)		 Jones B. C. et al.,
Unpublished		 −0.90 0.0008 8
12436 Anxiety, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an
elevated zero maze in 60 to 120-day-old males only during first 5 min [% time]		 Cook M. et al.,
Unpublished		 0.56 0.0133 18
12448 Anxiety, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an
elevated zero maze in 60 to 120-day-old males and females during 10 min [% time]		 Cook M. et al.,
Unpublished		 0.50 0.0294 19
12433 Anxiety, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an
elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec]		 Cook M. et al.,
Unpublished		 −0.56 0.0151 18
12446 Anxiety, restraint stress [15 min] and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an
elevated zero maze in 60 to 120-day-old males and females during first 5 min [% time]		 Cook M. et al.,
Unpublished		 0.54 0.0147 19
12337 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old females only during last 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.51 0.0290 18
12357 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old males and females during last 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.59 0.0066 19
12338 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old females only during 10 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.60 0.0076 18
12358 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old males and females during 10 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.48 0.0361 19
12347 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old males only during last 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.51 0.0274 18
12336 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old females only during first 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.54 0.0182 18
12339 Anxiety, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60
to 120-day-old females only during first 5 min [n beam breaks]		 Cook M. et al.,
Unpublished		 −0.57 0.0128 18
11437 Anxiety, percentage of time in open quadrants of a zero maze for males [%] (Philip et al., 2010) 0.90 0.0000 12
11439 Anxiety, time in open quadrants of a zero maze for males [sec] (Philip et al., 2010) 0.87 0.0000 12
11438 Anxiety, time in closed quadrants of a zero maze for males [sec] (Philip et al., 2010) −0.87 0.0000 12
11526 Novel open field behavior, vertical activity (rears) in the periphery from 0–15 min for males [n beam breaks] (Philip et al., 2010) 0.68 0.0132 12
11527 Novel open field behavior, vertical activity (rears) in the periphery from 15–30 min for males [n beam breaks] (Philip et al., 2010) 0.72 0.0064 12
11533 Novel open field behavior, vertical activity (rears) in the periphery from 0–60 min for males [n beam breaks] (Philip et al., 2010) 0.66 0.0163 12
12041 Novel open field behavior, vertical activity (rears) in the periphery from 15–30 min for males and females [n beam
breaks]		 (Philip et al., 2010) 0.65 0.0199 12
11813 Adult neurogenesis: BrdU-labeled cells in the rostral migratory stream 1 hr after BrdU injection for adult females
[density]		 (Philip et al., 2010) 0.86 0.0103 7
17455 3α,5α-THDOC in CIE males and females
17456 3α,5α-THDOC in CIE males Present results 0.78 0.0000 19
17454 3α,5α-THDOC in CTL females Present results 0.66 0.0123 13
17305 3α,5α-THP in CTL males and females Present results 0.57 0.0102 19
17449 3α,5α-THP in CTL females Present results 0.50 0.0375 17
17457 3α,5α-THDOC in CIE females Present results 0.65 0.0077 15
11708 Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0–
5 min for females [cm]		 (Philip et al., 2010) −0.65 0.0299 11
13576 Ethanol (20% v/v) consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in control
females, within-group change (phase 2 minus phase 1)		 Jones B. C. et al.,
Unpublished		 −0.90 0.0008 8
12368 Anxiety, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old females during whole 10 min test [% time]		 Cook M. et al.,
Unpublished		 0.66 0.0023 18
12366 Anxiety, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old females during first 5 min [% time]		 Cook M. et al.,
Unpublished		 0.62 0.0050 18
12438 Anxiety, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an
elevated zero maze in 60 to 120-day-old males only during 10 min [% time]		 Cook M. et al.,
Unpublished		 0.52 0.0259 18
12436 Anxiety, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an
elevated zero maze in 60 to 120-day-old males only during first 5 min [% time]		 Cook M. et al.,
Unpublished		 0.50 0.0349 18
10966 Anxiety (E5_TLA) following restraint stress (15 min) and ethanol injection (1.8 g/kg ip), locomotor activity in light-dark
box by 8–12 week-old males during a 5 min session [cm]		 Putman & Miles,
Unpublished		 0.82 0.0202 7
12357 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old males and females during last 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.63 0.0030 19
12347 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old males only during last 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.58 0.0108 18
12417 Anxiety, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60
to 120-day-old males and females during last 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.58 0.0082 19
12337 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old females only during last 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.50 0.0314 18
12348 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old males only during 10 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.48 0.0439 18
12338 Anxiety, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to
120-day-old females only during 10 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.50 0.0341 18
12407 Anxiety, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60
to 120-day-old males only during last 5 min [percentage of time]		 Cook M. et al.,
Unpublished		 0.53 0.0193 19
12397 Anxiety, saline treated (0.18 ml/kg ip, NOS group), time in open quadrants only during last 5 min of test using an
elevated zero maze for 60- to 120-day-old females [%]		 Cook M. et al.,
Unpublished		 0.49 0.0368 18
11437 Anxiety, percentage of time in open quadrants of a zero maze for males [%] (Philip et al., 2010) 0.77 0.0022 12
11438 Anxiety, time in closed quadrants of a zero maze for males [sec] (Philip et al., 2010) −0.74 0.0042 12
11439 Anxiety, time in open quadrants of a zero maze for males [sec] (Philip et al., 2010) 0.74 0.0042 12
11952 Anxiety, time in closed quadrants of a zero maze for males and females [sec] (Philip et al., 2010) −0.66 0.0181 12
11953 Anxiety, time in open quadrants of a zero maze for males and females [sec] (Philip et al., 2010) 0.66 0.0181 12
11951 Anxiety, percentage time in open quadrants of a zero maze for males and females [%] (Philip et al., 2010) 0.64 0.0219 12
11353 Novel open field behavior, locomotion in the center from 0–60 min for males [n beam breaks] (Philip et al., 2010) 0.60 0.0499 11
11920 Open field behavior, time in corners for males and females [min] (Philip et al., 2010) −0.59 0.0433 12
11853 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in
locomotion for males and females (last 15 min of morphine test (165–180 min) minus first 15 min after naloxone)
[cm difference]		 (Philip et al., 2010) −0.74 0.0042 12
11328 Morphine response (50 mg/kg ip), locomotion (open field) from 165–180 min after injection in an activity chamber
for males [cm]		 (Philip et al., 2010) −0.87 0.0001 11
11842 Morphine response (50 mg/kg ip), locomotion (open field) from 165–180 min after injection in an activity chamber
for males and females [cm]		 (Philip et al., 2010) −0.73 0.0049 12
11831 Morphine response (50 mg/kg ip), locomotion from 165–180 min after injection in an activity chamber for males
and females [n beam breaks]		 (Philip et al., 2010) −0.72 0.0064 12
11317 Morphine response (50 mg/kg ip), locomotion from 165–180 min after injection in an activity chamber for males [n
beam breaks]		 (Philip et al., 2010) −0.82 0.0011 11
11339 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in
locomotion for males (last 15 min of morphine test (165–180 min) minus first 15 min after naloxone) [cm
difference]		 (Philip et al., 2010) −0.78 0.0030 11
11596 Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in
locomotion for females (last 15 min of morphine test (165–180 min) minus first 15 min after naloxone) [cm
difference]		 (Philip et al., 2010) −0.73 0.0056 12
11583 Morphine response (50 mg/kg ip), locomotion (open field) from 0–15 min after injection in an activity chamber for
females [cm]		 (Philip et al., 2010) −0.76 0.0031 12
11327 Morphine response (50 mg/kg ip), locomotion (open field) from 150–165 min after injection in an activity chamber
for males [cm]		 (Philip et al., 2010) −0.69 0.0162 11
11841 Morphine response (50 mg/kg ip), locomotion (open field) from 150–165 min after injections in an activity
chamber for males and females [cm]		 (Philip et al., 2010) −0.69 0.0118 12
11830 Morphine response (50 mg/kg ip), locomotion from 150–165 min after injection in an activity chamber for males
and females [n beam breaks]		 (Philip et al., 2010) −0.69 0.0118 12
11316 Morphine response (50 mg/kg ip), locomotion from 150–165 min after injection in an activity chamber for males [n
beam breaks]		 (Philip et al., 2010) −0.65 0.0267 11
11585 Morphine response (50 mg/kg ip), locomotion (open field) from 165–180 min after injection in an activity chamber
for females [cm]		 (Philip et al., 2010) −0.76 0.0031 12
11572 Morphine response (50 mg/kg ip), locomotion from 0–15 min after injection in an activity chamber for females [n
beam breaks]		 (Philip et al., 2010) −0.64 0.0219 12
11627 Morphine response (50 mg/kg ip), vertical activity (rears) from 15–30 min after injection in an activity chamber for
females [n beam breaks]		 (Philip et al., 2010) −0.67 0.0147 12
11574 Morphine response (50 mg/kg ip), locomotion from 165–180 min after injection in an activity chamber for females
[n beam breaks]		 (Philip et al., 2010) −0.70 0.0094 12
12890 Activity of 13-week old females, total counts of fine movements and ambulatory activity [counts/unit time] (Andreux et al., 2012) 1.00 0.0000 6

Variation in 3α,5α-THDOC levels across the BXD population was linked to behavioral or neurochemical phenotypes previously characterized across these strains by other laboratories and whose data are available in GeneNetwork. GN ID refers to the GeneNetwork BXD phenotype ID for each trait.